Cargando…

Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.

Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like sympt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilleece, M. H., Scarffe, J. H., Ghosh, A., Heyworth, C. M., Bonnem, E., Testa, N., Stern, P., Dexter, T. M.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1992
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977892/ https://www.ncbi.nlm.nih.gov/pubmed/1637669

Ejemplares similares

Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.
por: Steward, W. P., et al.
Publicado: (1989)

Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
por: Thatcher, N., et al.
Publicado: (1989)

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
por: Bronchud, M. H., et al.
Publicado: (1987)

Interleukin-4 (IL4) and Interleukin-4 receptor (IL4RA) polymorphisms in asthma: a case control study
por: Isidoro-García, María, et al.
Publicado: (2005)

Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
por: Honkoop, A. H., et al.
Publicado: (1996)

Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.
por: Steward, W. P., et al.
Publicado: (1990)

Role of interleukin 4 (IL4) and interleukin 6 (IL6) in the pathogenesis and prognosis of childhood primary immune thrombocytopenia
por: Zakaria, Marwa, et al.
Publicado: (2023)

Interleukin-4 (IL-4) enhances and soluble interleukin-4 receptor (sIL-4R) inhibits histamine release from peripheral blood basophils and mast cells in vitro and in vivo
por: Niggemann, B., et al.
Publicado: (1997)

Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2.
por: Baars, J. W., et al.
Publicado: (1992)

Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells
por: Yao, Yongxue, et al.
Publicado: (2005)

Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis
por: Iwaszko, Milena, et al.
Publicado: (2021)

Central Venous Catheter Placement: Extending the Role of the Nurse
por: Fitzsimmons, C L, et al.
Publicado: (1997)

Interleukin (IL)-6 Directs the Differentiation of IL-4–producing CD4(+) T Cells
por: Rincón, Mercedes, et al.
Publicado: (1997)

Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4- producing cells
Publicado: (1990)

Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis
Publicado: (1995)

IL4‐10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10
por: Steen‐Louws, C., et al.
Publicado: (2018)

Interleukin 4 (IL-4) or IL-7 Prevents the Death of Resting T Cells: Stat6 Is Probably Not Required for the Effect of IL-4
por: Vella, Anthony, et al.
Publicado: (1997)

Assessment of Interleukins IL-4, IL-6, IL-8, IL-10 in Acute Urticaria
por: Papadopoulos, Jordan, et al.
Publicado: (2014)

Human Non-Germinal Center B Cell Interleukin (IL)-12 Production Is Primarily Regulated by T Cell Signals CD40 Ligand, Interferon γ, and IL-10: Role of B Cells in the Maintenance of T Cell Responses
por: Schultze, Joachim L., et al.
Publicado: (1999)

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
por: Ravaud, A., et al.
Publicado: (1994)

Cytokines Interleukin 4 (IL-4) and Interleukin 10 (IL-10) Gene Polymorphisms as Potential Host Susceptibility Factors in Virus-Induced Encephalitis
por: Yu, Ying, et al.
Publicado: (2017)

Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.
por: Ghosh, A. K., et al.
Publicado: (1990)

Recombinant p35 from Bacteria Can Form Interleukin (IL-)12, but Not IL-35
por: Aparicio-Siegmund, Samadhi, et al.
Publicado: (2014)

Interleukin (IL)-4 Induces Leukocyte Infiltration In Vivo by an Indirect Mechanism
por: Ratthé, Claude, et al.
Publicado: (2009)

Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.
por: Thatcher, N., et al.
Publicado: (1990)

Induction of interleukin 4 (IL-4) expression in T helper (Th) cells is not dependent on IL-4 from non-Th cells
Publicado: (1994)

Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes
por: Junttila, Ilkka S.
Publicado: (2018)

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.
por: Bronchud, M. H., et al.
Publicado: (1988)

Rescue and evaluation of a recombinant PRRSV expressing porcine Interleukin-4
por: Li, Zhijun, et al.
Publicado: (2015)

FTY-720P Suppresses Osteoclast Formation by Regulating Expression of Interleukin-6 (IL-6), Interleukin-4 (IL-4), and Matrix Metalloproteinase 2 (MMP-2)
por: Zhang, Dawei, et al.
Publicado: (2016)

The association between interleukin-4 -590C/T genetic polymorphism, IL-4 serum level, and advanced endometriosis
por: Malutan, Andrei M., et al.
Publicado: (2016)

A preliminary study on the association of single nucleotide polymorphisms of interleukin 4 (IL4), IL13, IL4 receptor alpha (IL4Rα) & Toll-like receptor 4 (TLR4) genes with asthma in Indian adults
por: Davoodi, Parisa, et al.
Publicado: (2015)

Effect of interleukin (IL)-35 on IL-17 expression and production by human CD4(+) T cells
por: Okada, Kosuke, et al.
Publicado: (2017)

Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)
por: Punt, C. J., et al.
Publicado: (1990)

Studies on the in vivo production of a lymphokine activity, interleukin 3 (IL-3) elaborated by lymphocytes and a myeloid leukaemic line in vitro and the fate of IL-3 dependent cell lines.
por: Garland, J. M., et al.
Publicado: (1983)

An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13- induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors
Publicado: (1993)

Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells
Publicado: (1989)

In Vivo Priming of Cd4 T Cells That Produce Interleukin (Il)-2 but Not IL-4 or Interferon (Ifn)-γ, and Can Subsequently Differentiate into IL-4–Or IFN-γ–Secreting Cells
por: Wang, Xiaowen, et al.
Publicado: (2001)

Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity
por: Saeidi, R, et al.
Publicado: (2012)

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
Publicado: (1985)

Cannot write session to /tmp/vufind_sessions/sess_26uvnc9t8jp7nhk87q06njcntl